Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients (COMED)
Background: Hypo- and hypernatremia are common in hospitalized patients. The differential diagnosis of dysnatremia is challenging.
Osmotically inadequate secretion of antidiuretic hormone (ADH) is the predominant mechanism in most dysnatremic disorders. ADH measurement is cumbersome. It is derived from a larger precursor peptide along with copeptin, which is a more stable peptide directly mirroring the production of ADH.
Objective: To evaluate the additional value of copeptin to improve a currently used algorithm in the differential diagnosis of (A) severe hypoosmolar hypo- and (B) severe hypernatremia.
Design: Prospective observational study.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients|
- diagnostic accuracy of copeptin within hospital stay [ Time Frame: participants will be followed for up to 1 year ] [ Designated as safety issue: No ]diagnostic accuracy will be determined by receiver operated curve (ROC) analysis. The study is powered to detect a difference of copeptin levels between patients with partial central diabetes insipidus (DI) and patients with primary polydipsia.
|Study Start Date:||October 2011|
|Estimated Study Completion Date:||August 2015|
|Estimated Primary Completion Date:||August 2015 (Final data collection date for primary outcome measure)|
hospitalized patients with hyponatremia
Please refer to this study by its ClinicalTrials.gov identifier: NCT01456533
|Aarau, Aargau, Switzerland|
|Basel, Switzerland, 4031|
|Principal Investigator:||Mirjam Christ-Crain, MD, PhD||University Hospital, Basel, Switzerland|
|Principal Investigator:||Beat Müller, MD||Kantonsspital Aarau, University Hospital Basel|